CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Net product sales	$ 418,022	$ 333,893	$ 780,400	$ 652,633
Sanofi collaboration revenue	142,595	85,529	273,103	184,802
Bayer HealthCare collaboration revenue	97,295	31,104	222,607	46,011
Technology licensing and other revenue	7,788	7,116	15,330	13,860
Total revenues	665,700	457,642	1,291,440	897,306
Expenses:
Research and development	294,501	187,463	581,880	367,762
Selling, general, and administrative	102,414	72,463	211,264	149,723
Cost of goods sold	29,945	27,283	57,418	55,304
Cost of collaboration manufacturing	16,434	12,330	32,533	13,364
Total expenses	443,294	299,539	883,095	586,153
Income from operations	222,406	158,103	408,345	311,153
Other income (expense):
Investment income	1,677	954	2,614	1,410
Interest expense	(10,177)	(11,365)	(21,790)	(23,040)
Loss on extinguishment of debt	(10,787)	0	(10,787)	0
Total other income (expense)	(19,287)	(10,411)	(29,963)	(21,630)
Income before income taxes	203,119	147,692	378,382	289,523
Income tax expense	(110,384)	(60,316)	(220,204)	(103,273)
Net income	92,735	87,376	158,178	186,250
Net income per share - basic	$ 0.92	$ 0.89	$ 1.58	$ 1.91
Net income per share - diluted	$ 0.82	$ 0.79	$ 1.40	$ 1.69
Weighted average shares outstanding - basic	100,391	97,700	100,085	97,289
Weighted average shares outstanding - diluted	113,032	111,060	113,121	110,305
Statements of Comprehensive Income
Net income	92,735	87,376	158,178	186,250
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	2,798	(1,785)	5,451	(2,263)
Comprehensive income	$ 95,533	$ 85,591	$ 163,629	$ 183,987